Latest news with #MaulikPatel
Time of India
a day ago
- Business
- Time of India
Epigral to expand wind-solar hybrid power plant to 38.14 MW, Manufacturing News, ET Manufacturing
Advt Specialty chemical manufacturer Epigral said on Wednesday it will more than double its wind-solar hybrid power capacity to 38.14 megawatt (MW) from 18.34 MW through a Rs 21.38-crore company will invest Rs 21.38 crore for a 26 per cent stake in a special purpose vehicle (SPV) created in partnership with Prozeal Green Energy Ltd to add 19.80 MW renewable strategic partnership will be formalised for 25 years through an energy subscription agreement and share subscription and shareholder agreement between the two companies, Epigral said in a capacity expansion is expected to be commissioned by the fourth quarter of FY26 and will help meet rising power demands from upcoming projects, the company said."The capacity expansion will be important to meet our rising energy demands," Epigral Chairman and Managing Director Maulik Patel has announced plans to expand capacity for CPVC Resin to 150,000 tonnes per annum and Epichlorohydrin (ECH) to 100,000 tonnes per annum. The company recently commissioned a chlorotoluene value chain plant at its Dahej facility in renewable energy expansion reflects the company's strategy to secure clean power while pursuing aggressive growth in the specialty chemicals sector
Time of India
a day ago
- Business
- Time of India
Epigral to expand wind-solar hybrid power plant to 38.14 MW
Specialty chemical manufacturer Epigral said on Wednesday it will more than double its wind-solar hybrid power capacity to 38.14 megawatt (MW) from 18.34 MW through a Rs 21.38-crore investment. The company will invest Rs 21.38 crore for a 26 per cent stake in a special purpose vehicle (SPV) created in partnership with Prozeal Green Energy Ltd to add 19.80 MW renewable capacity. The strategic partnership will be formalised for 25 years through an energy subscription agreement and share subscription and shareholder agreement between the two companies, Epigral said in a statement. The capacity expansion is expected to be commissioned by the fourth quarter of FY26 and will help meet rising power demands from upcoming projects, the company said. "The capacity expansion will be important to meet our rising energy demands," Epigral Chairman and Managing Director Maulik Patel said. Live Events Epigral has announced plans to expand capacity for CPVC Resin to 150,000 tonnes per annum and Epichlorohydrin (ECH) to 100,000 tonnes per annum. The company recently commissioned a chlorotoluene value chain plant at its Dahej facility in Gujarat. The renewable energy expansion reflects the company's strategy to secure clean power while pursuing aggressive growth in the specialty chemicals sector .
Entrepreneur
06-05-2025
- Business
- Entrepreneur
Epigral Posts 13% YoY Rise in PAT for Q4FY25 Reaching INR 87 Crore
Epigral also announced major expansion plans to support future growth. Capacity for CPVC Resin and Epichlorohydrin is set to double, with new facilities expected to be operational in the first half of FY2027 You're reading Entrepreneur India, an international franchise of Entrepreneur Media. Epigral, an integrated chemical manufacturer, reported a robust set of financial results for the quarter and full year ended March 31, 2025, according to its latest regulatory filing. The company posted a 13 per cent year-on-year (YoY) rise in profit after tax (PAT) for Q4FY25, reaching INR 87 crore, compared to INR 77 crore in the same quarter last year. Revenue for the quarter surged 20 per cent to INR 631 crore, driven largely by volume growth in the high-margin derivatives & specialty segment. The company's financial health showed marked improvement, with return on capital employed (ROCE) climbing to 25 per cent in FY2025, up from 18 per cent a year ago. Its net debt to EBITDA ratio more than halved to 0.7x from 2.0x, while CRISIL upgraded Epigral's credit rating to AA, up from AA-, reflecting enhanced fiscal stability and operational performance. Chairman and managing director, Maulik Patel, emphasized the significance of the company's trajectory, stating, "We ended FY2025 with the highest ever revenue of INR 2,565 crore, a growth of 33 per cent compared to the previous year. This growth is on account of volume rise of 11 per cent, majorly from high value products." Notably, the derivatives & specialty segment played a pivotal role in this performance, growing by 24 per cent in volume terms and increasing its revenue contribution to 54 per cent from 45 per cent in FY2024. The company also raised INR 333 crore through a qualified institutional placement (QIP), which was used to fund its ongoing capital expenditure of INR 195 crore during FY2025. Looking ahead, Patel noted, "We are geared up and strengthened our position to grow further, by focusing on import substitute products, further diversifying and increasing derivatives & specialty business and with prudence allocation of capital, rewarding our stakeholders." The board has proposed a final dividend of INR 3.5 per share, bringing the total dividend for FY2025 to INR six per share.
Time of India
05-05-2025
- Business
- Time of India
Epigral Q4 net profit rises 13% to Rs 87 crore
AHMEDABAD: Integrated chemical maker Epigral on Monday reported a 13% jump in net profit to Rs 87 crore for the March quarter, up from Rs 77 crore in the year-ago period. The company's revenue from operations for the quarter also rose 20% to Rs 631 crore, compared to Rs 526 crore in Q4 last year. For the full fiscal FY25, the company logged a 33% rise in revenue to a record Rs 2,565 crore. Chairman and Managing Director Maulik Patel attributed the growth to an 11% rise in overall volumes, with high-value products driving the surge. 'Derivatives and Specialty business volume grew by around 24% in FY25, contributing 54% to revenue versus 45% in FY24,' he said. You Can Also Check: Ahmedabad AQI | Weather in Ahmedabad | Bank Holidays in Ahmedabad | Public Holidays in Ahmedabad The company also announced plans to expand its CPVC and Epichlorohydrin capacity, with new facilities set to go live in the first half of FY27. Founded in 2007, Epigral is India's first manufacturer of Epichlorohydrin using 100% renewable feedstock and runs the country's largest CPVC resin plant.
Time of India
05-05-2025
- Business
- Time of India
Epigral Q4 net profit rises 13% to Rs 87 crore
Integrated chemical manufacturer Epigral on Monday reported a 13 per cent increase in net profit to Rs 87 crore for the fourth quarter of the last fiscal. The company had posted a net profit of Rs 77 crore in the year-ago period. #Pahalgam Terrorist Attack Pakistan's economy has much more to lose than India's due to the ongoing tensions, warns Moody's Ratings The day Pakistan got the power to poke India India demands ADB to stop funds to Pakistan as fallout of Pahalgam terror attack deepens Its total revenue rose 20 per cent in the fourth quarter to Rs 631 crore from Rs 526 crore a year ago. For the full fiscal 2024-25, the company reported a 33 per cent year-on-year increase in revenue to Rs 2,565 crore. by Taboola by Taboola Sponsored Links Sponsored Links Promoted Links Promoted Links You May Like Villas For Sale in Dubai Might Surprise You Villas In Dubai | Search Ads Get Rates Undo Epigral Chairman and Managing Director Maulik Patel said the company reported "the highest ever revenue" in 2024-25. "This growth is on account of a volume rise of 11 per cent, majorly from high-value products. Derivatives and Specialty business volume grew by around 24 per cent in FY2025 and its contribution to revenue touched 54 per cent compared to 45 per cent in FY24," he said in a statement. Live Events The company announced expanding its CPVC and Epichlorohydrin capacity, which are expected to be commissioned in the 1st half of FY2027. The integrated complex will further strengthen after these projects reach optimum utilisation, he added. The company is geared up and focusing on importing substitute products, further diversifying and increasing the derivatives and speciality business, Patel said. Established in 2007, Epigral is notable for being the first company in India to manufacture Epichlorohydrin ( ECH ), using 100 per cent renewable resources, and it operates the country's largest CPVC resin plant.
